{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:03:43Z","timestamp":1757617423333,"version":"3.44.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Noster Inc","award":["Noster Inc"],"award-info":[{"award-number":["Noster Inc"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Aims<\/jats:title>\n            <jats:p>The oral administration of linoleic acid immediately before glucose tolerance test (OGTT) ameliorated postprandial hyperglycemia via GPR120 pathway in normal and type 1 diabetes (T1DM) rats. Linoleic acid could promote inflammatory mediators, but 10-hydroxy-<jats:italic>cis<\/jats:italic>-12-octadecenoic acid (HYA) converted from linoleic acid by <jats:italic>Lactobacillus plantarum<\/jats:italic> has higher GPR120 agonistic activity without promoting inflammatory mediators. This study examined whether the oral-administration of HYA immediately before OGTT also ameliorated the postprandial hyperglycemia in normal rats and T1DM rats injected with bolus insulin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Normal and T1DM male Sprague-Dawley rats received HYA immediately before OGTT. Other T1DM rats were given HYA and Humulin R immediately before OGTT. We measured the concentration of glucose, insulin, glucagon-like peptide 1 (GLP-1) and cholecystokinin in blood before and after OGTT. We also measured the amount of glucose in the gastric tract after OGTT, and the amount of uptake of methyl-\u03b1-D-glucopyranoside in CACO-2 cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Postprandial hyperglycemia was ameliorated by HYA in normal rats, and the postprandial blood glucose levels were slowly elevated by HYA in the T1DM model rats. HYA partially inhibited the uptake of methyl-\u03b1-D-glucopyranoside in CACO-2 cells. HYA slowed gastric motility and increased the plasma GLP-1 and cholecystokinin levels in normal rats. HYA also ameliorated the postprandial hyperglycemia in T1DM rats given bolus insulin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Oral administration of HYA immediately before OGTT ameliorated postprandial hyperglycemia through inhibition of glucose absorption and slowing of gastric motility in normal rats. Furthermore, this beneficial effect of HYA was also revealed in T1DM rats injected with bolus insulin.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00592-025-02459-6","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T07:06:59Z","timestamp":1738566419000},"page":"1337-1345","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HYA ameliorated postprandial hyperglycemia in type 1 diabetes model rats with bolus insulin treatment"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5225-6989","authenticated-orcid":false,"given":"Yuta","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Narumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Yamagishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Yonejima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Iseki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimitsu","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"2459_CR1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1152\/physrev.00041.2018","volume":"100","author":"I Kimura","year":"2020","unstructured":"Kimura I, Ichimura A, Ohue-Kitano R, Igarashi M (2020) Free fatty acid receptors in health and disease. Physiol Rev 100:171\u2013210","journal-title":"Physiol Rev"},{"key":"2459_CR2","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3390\/ijms17040450","volume":"17","author":"J Miyamoto","year":"2016","unstructured":"Miyamoto J, Hasegawa S, Kasubuchi M, Ichimura A, Nakajima A, Kimura I (2016) Nutritional signaling via free fatty acid receptors. Int J Mol Sci 17:450","journal-title":"Int J Mol Sci"},{"key":"2459_CR3","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1038\/s41467-019-11978-0","volume":"10","author":"J Miyamoto","year":"2019","unstructured":"Miyamoto J, Igarashi M, Watanabe K, Karaki SI, Mukouyama H, Kishino S, Li X, Ichimura A, Irie J, Sugimoto Y, Mizutani T, Sugawara T, Miki T, Ogawa J, Drucker DJ, Arita M, Itoh H, Kimura I (2019) Gut microbiota confers host resistance to obesity by metabolizing dietary polyunsaturated fatty acids. Nat Commun 10:4007","journal-title":"Nat Commun"},{"key":"2459_CR4","doi-asserted-by":"publisher","first-page":"1197743","DOI":"10.3389\/fphar.2023.1197743","volume":"14","author":"Y Yamamoto","year":"2023","unstructured":"Yamamoto Y, Narumi K, Yamagishi N, Nishi T, Ito T, Iseki K, Kobayashi M, Kanai Y (2023) Oral administration of linoleic acid immediately before glucose load ameliorates postprandial hyperglycemia. Front Pharmacol 14:1197743","journal-title":"Front Pharmacol"},{"key":"2459_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.immuni.2014.02.009","volume":"40","author":"CD Buckley","year":"2014","unstructured":"Buckley CD, Gilroy DW, Serhan CN (2014) Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 40:315\u2013327","journal-title":"Immunity"},{"key":"2459_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1263\/jbb.100.355","volume":"100","author":"J Ogawa","year":"2005","unstructured":"Ogawa J, Kishino S, Ando A, Sugimoto S, Mihara K, Shimizu S (2005) Production of conjugated fatty acids by lactic acid bacteria. J Biosci Bioeng 100:355\u2013364","journal-title":"J Biosci Bioeng"},{"key":"2459_CR7","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1074\/jbc.M114.610733","volume":"290","author":"J Miyamoto","year":"2015","unstructured":"Miyamoto J, Mizukure T, Park SB, Kishino S, Kimura I, Hirano K, Bergamo P, Rossi M, Suzuki T, Arita M, Ogawa J, Tanabe S (2015) A gut microbial metabolite of linoleic acid, 10-hydroxy-cis-12-octadecenoic acid, ameliorates intestinal epithelial barrier impairment partially via GPR40-MEK-ERK pathway. J Biol Chem 290:2902\u20132918","journal-title":"J Biol Chem"},{"key":"2459_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jphs.2018.06.015","volume":"138","author":"S Ikeguchi","year":"2018","unstructured":"Ikeguchi S, Izumi Y, Kitamura N, Kishino S, Ogawa J, Akaike A, Kume T (2018) Inhibitory effect of the gut microbial linoleic acid metabolites, 10-oxo-trans-11-octadecenoic acid and 10-hydroxy-cis-12-octadecenoic acid, on BV-2 microglial cell activation. J Pharmacol Sci 138:9\u201315","journal-title":"J Pharmacol Sci"},{"key":"2459_CR9","doi-asserted-by":"publisher","DOI":"10.3791\/56672","author":"C Nagy","year":"2018","unstructured":"Nagy C, Einwallner E (2018) Study of in vivo glucose metabolism in high-fat diet-fed mice using oral glucose tolerance test (OGTT) and insulin tolerance test (ITT). J Vis Exp. https:\/\/doi.org\/10.3791\/56672","journal-title":"J Vis Exp"},{"key":"2459_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2337\/db11-1029","volume":"61","author":"V Gorboulev","year":"2012","unstructured":"Gorboulev V, Schurmann A, Vallon V, Kipp H, Jaschke A, Klessen D, Friedrich A, Scherneck S, Rieg T, Cunard R, Veyhl-Wichmann M, Srinivasan A, Balen D, Breljak D, Rexhepaj R, Parker HE, Gribble FM, Reimann F, Lang F, Wiese S, Sabolic I, Sendtner M, Koepsell H (2012) Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61:187\u2013196","journal-title":"Diabetes"},{"key":"2459_CR11","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/jdi.13255","volume":"11","author":"R Sano","year":"2020","unstructured":"Sano R, Shinozaki Y, Ohta T (2020) Sodium-glucose cotransporters: functional properties and pharmaceutical potential. J Diabetes Investig 11:770\u2013782","journal-title":"J Diabetes Investig"},{"key":"2459_CR12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1124\/jpet.113.203364","volume":"345","author":"DR Powell","year":"2013","unstructured":"Powell DR, Smith M, Greer J, Harris A, Zhao S, DaCosta C, Mseeh F, Shadoan MK, Sands A, Zambrowicz B, Ding ZM (2013) LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium\/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther 345:250\u2013259","journal-title":"J Pharmacol Exp Ther"},{"key":"2459_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1124\/jpet.117.240820","volume":"362","author":"DR Powell","year":"2017","unstructured":"Powell DR, Smith MG, Doree DD, Harris AL, Greer J, DaCosta CM, Thompson A, Jeter-Jones S, Xiong W, Carson KG, Goodwin NC, Harrison BA, Rawlins DB, Strobel ED, Gopinathan S, Wilson A, Mseeh F, Zambrowicz B, Ding ZM (2017) LX2761, a sodium\/glucose cotransporter 1 inhibitor restricted to the intestine, improves glycemic control in mice. J Pharmacol Exp Ther 362:85\u201397","journal-title":"J Pharmacol Exp Ther"},{"key":"2459_CR14","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.2337\/dc14-2806","volume":"38","author":"AT Sands","year":"2015","unstructured":"Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, Buse JB, Banks P, Heptulla R, Rendell M, Cefalu WT, Strumph P (2015) Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 38:1181\u20131188","journal-title":"Diabetes Care"},{"key":"2459_CR15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1152\/physrev.00031.2014","volume":"97","author":"RE Steinert","year":"2017","unstructured":"Steinert RE, Feinle-Bisset C, Asarian L, Horowitz M, Beglinger C, Geary N (2017) Ghrelin, CCK, GLP-1, and PYY(3\u201336): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol Rev 97:411\u2013463","journal-title":"Physiol Rev"},{"key":"2459_CR16","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.3748\/wjg.v26.i25.3562","volume":"26","author":"WK Huang","year":"2020","unstructured":"Huang WK, Xie C, Young RL, Zhao JB, Ebendorff-Heidepriem H, Jones KL, Rayner CK, Wu TZ (2020) Development of innovative tools for investigation of nutrient-gut interaction. World J Gastroenterol 26:3562\u20133576","journal-title":"World J Gastroenterol"},{"key":"2459_CR17","doi-asserted-by":"publisher","first-page":"107951","DOI":"10.1016\/j.diabres.2019.107951","volume":"159","author":"X Wang","year":"2020","unstructured":"Wang X, Xie C, Marathe CS, Malbert CH, Horowitz M, Jones KL, Rayner CK, Sun Z, Wu T (2020) Disparities in gastric emptying and postprandial glycaemia between Han Chinese and caucasians with type 2 diabetes. Diabetes Res Clin Pract 159:107951","journal-title":"Diabetes Res Clin Pract"},{"key":"2459_CR18","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1080\/00365521.2018.1530297","volume":"53","author":"JF Rehfeld","year":"2018","unstructured":"Rehfeld JF, Knop FK, Asmar A, Madsbad S, Holst JJ, Asmar M (2018) Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. Scand J Gastroenterol 53:1429\u20131432","journal-title":"Scand J Gastroenterol"},{"key":"2459_CR19","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00125-018-4804-y","volume":"62","author":"C Thivolet","year":"2019","unstructured":"Thivolet C, Marchand L, Chikh K (2019) Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 1 diabetes: effects of residual C-peptide. Diabetologia 62:593\u2013597","journal-title":"Diabetologia"},{"key":"2459_CR20","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/14740338.2019.1626823","volume":"18","author":"EM Lamos","year":"2019","unstructured":"Lamos EM, Hedrington M, Davis SN (2019) An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors. Expert Opin Drug Saf 18:691\u2013701","journal-title":"Expert Opin Drug Saf"},{"key":"2459_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1517\/14740338.2013.752813","volume":"12","author":"SA Stein","year":"2013","unstructured":"Stein SA, Lamos EM, Davis SN (2013) A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf 12:153\u2013175","journal-title":"Expert Opin Drug Saf"},{"key":"2459_CR22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ejphar.2012.09.024","volume":"696","author":"S Fukuda-Tsuru","year":"2012","unstructured":"Fukuda-Tsuru S, Anabuki J, Abe Y, Yoshida K, Ishii S (2012) A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. Eur J Pharmacol 696:194\u2013202","journal-title":"Eur J Pharmacol"},{"key":"2459_CR23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s12325-014-0100-5","volume":"31","author":"JM Tibaldi","year":"2014","unstructured":"Tibaldi JM (2014) Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes. Adv Ther 31:289\u2013317","journal-title":"Adv Ther"},{"key":"2459_CR24","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1210\/clinem\/dgac618","volume":"108","author":"K Edwards","year":"2023","unstructured":"Edwards K, Li X, Lingvay I (2023) Clinical and safety outcomes with GLP-1 receptor agonists and SGLT2 inhibitors in type 1 diabetes: a real-world study. J Clin Endocrinol Metab 108:920\u2013930","journal-title":"J Clin Endocrinol Metab"},{"key":"2459_CR25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1124\/jpet.116.232025","volume":"358","author":"R Ohgaki","year":"2016","unstructured":"Ohgaki R, Wei L, Yamada K, Hara T, Kuriyama C, Okuda S, Ueta K, Shiotani M, Nagamori S, Kanai Y (2016) Interaction of the sodium\/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2. J Pharmacol Exp Ther 358:94\u2013102","journal-title":"J Pharmacol Exp Ther"},{"key":"2459_CR26","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.3390\/cells10081981","volume":"10","author":"JO Adeghate","year":"2021","unstructured":"Adeghate JO, D\u2019souza C, K\u00e1ntor O, Tariq S, Souid AK, Adeghate E (2021) Early (5-day) onset of diabetes mellitus causes degeneration of photoreceptor cells, overexpression of incretins, and increased cellular bioenergetics in rat retina. Cells 10:1981","journal-title":"Cells"},{"key":"2459_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.preteyeres.2010.09.001","volume":"30","author":"CJ Chiu","year":"2011","unstructured":"Chiu CJ, Taylor A (2011) Dietary hyperglycemia, glycemic index and metabolic retinal diseases. Prog Retin Eye Res 30:18\u201353","journal-title":"Prog Retin Eye Res"},{"key":"2459_CR28","doi-asserted-by":"publisher","first-page":"113439","DOI":"10.1016\/j.biopha.2022.113439","volume":"153","author":"PV Dludla","year":"2022","unstructured":"Dludla PV, Nkambule BB, Cirilli I, Marcheggiani F, Mabhida SE, Ziqubu K, Ntamo Y, Jack B, Nyambuya TM, Hanser S, Mazibuko-Mbeje SE (2022) Capsaicin, its clinical significance in patients with painful diabetic neuropathy. Biomed Pharmacother 153:113439","journal-title":"Biomed Pharmacother"},{"key":"2459_CR29","doi-asserted-by":"publisher","first-page":"6396","DOI":"10.3390\/ijms23126396","volume":"23","author":"NA Mohd Nor","year":"2022","unstructured":"Mohd Nor NA, Budin SB, Zainalabidin S, Jalil J, Sapian S, Jubaidi FF, Mohamad Anuar NN (2022) The role of polyphenol in modulating associated genes in diabetes-induced vascular disorders. Int J Mol Sci 23:6396","journal-title":"Int J Mol Sci"},{"key":"2459_CR30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1089\/dia.2009.0112","volume":"12","author":"E Cobry","year":"2010","unstructured":"Cobry E, McFann K, Messer L, Gage V, VanderWel B, Horton L, Chase HP (2010) Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diabetes Technol Ther 12:173\u2013177","journal-title":"Diabetes Technol Ther"},{"key":"2459_CR31","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.2337\/dc10-0692","volume":"33","author":"YM Luijf","year":"2010","unstructured":"Luijf YM, van Bon AC, Hoekstra JB, Devries JH (2010) Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care 33:2152\u20132155","journal-title":"Diabetes Care"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-025-02459-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-025-02459-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-025-02459-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T04:37:08Z","timestamp":1757133428000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-025-02459-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["2459"],"URL":"https:\/\/doi.org\/10.1007\/s00592-025-02459-6","relation":{},"ISSN":["1432-5233"],"issn-type":[{"type":"electronic","value":"1432-5233"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"assertion":[{"value":"22 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by funding from Noster Inc., who also supplied the HYA. Noster Inc. had no other roles in this study. The authors declare no other conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The protocol of animal experiments was approved by the Wakayama Medical University Animal Experiment Committee on July 1, 2019 (No. 883).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal participant"}}]}}